Can Edgewise Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 22.61 — current assets exceed current liabilities.

Where does Edgewise Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Edgewise Therapeutics, Inc. EWTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$33.21M-33.5%	$61.15M+46.8%	$46M+2.7%	$43.4M-0.2%	$49.92M+65.0%
Prepaid expenses and other current assets	$10.23M+50.6%	$13.28M+150%	$10.56M+53.0%	$9.26M+20.5%	$6.79M-21.7%
Total current assets	$509.79M+15.0%	$543.39M+14.3%	$573.9M+14.9%	$603.26M+16.1%	$443.18M-18.1%
Property and equipment, net	$7.4M-17.7%	$7.83M-17.6%	$8.13M-18.4%	$8.6M-13.2%	$8.99M-11.7%
Operating lease right-of-use assets	$1.33M-12.7%	$1.39M-11.6%	$1.44M-11.2%	$1.48M-27.5%	$1.53M-30.4%
Total assets	$518.52M+14.1%	$552.6M+13.5%	$583.47M+14.1%	$613.33M+15.4%	$454.39M-18.0%
Accounts payable	$7.29M-17.0%	$6.01M+7.7%	$6.16M+9.0%	$8.32M+22.3%	$8.79M+86.1%
Accrued expenses	$5.68M+42.9%	$12.43M+23.6%	$8M+29.3%	$5.64M+32.8%	$3.97M+35.9%
Operating lease liabilities, current	$1.02M+1.6%	$1.01M+1.8%	$1.01M+1.6%	$1M+1.6%	$1M+1.7%
Total current liabilities	$22.54M+6.8%	$27.37M+14.7%	$21.65M+14.2%	$20.9M+21.7%	$21.12M+44.6%
Operating lease liabilities, non-current	$2.78M-22.0%	$2.98M-20.4%	$3.17M-8.0%	$3.37M-15.8%	$3.56M-16.6%
Total liabilities	$25.32M+2.6%	$30.35M+9.9%	$24.82M+10.8%	$24.26M+14.6%	$24.67M+30.8%
Common stock	$10K+11.1%	$10K+11.1%	$10K+11.1%	$10K+11.1%	$9K0.0%
Additional paid-in capital	$1.09B+28.3%	$1.07B+27.5%	$1.05B+27.5%	$1.04B+27.9%	$848.68M+4.9%
Retained earnings	-$595.38M-42.0%	-$546.37M-44.3%	-$496.16M-46.4%	-$455.49M-49.4%	-$419.37M-53.5%
Accumulated other comprehensive income (loss)	-$252K-163%	$677K+61.2%	$701K-33.3%	$204K+119%	$401K+147%
Total stockholders' equity	$493.2M+14.8%	$522.26M+13.7%	$558.65M+14.3%	$589.07M+15.4%	$429.72M-19.7%
Total liabilities and stockholders' equity	$518.52M+14.1%	$552.6M+13.5%	$583.47M+14.1%	$613.33M+15.4%	$454.39M-18.0%
Net Investment in Lease	$1.33M-12.7%	$1.39M-11.6%	$1.44M-11.2%	$1.48M-27.5%	$1.53M-30.4%
Operating lease right-of-use assets	$1.33M-12.7%	$1.39M-11.6%	$1.44M-11.2%	$1.48M-27.5%	$1.53M-30.4%
Operating Lease Right-of-Use Assets in Other Assets	$1.33M-12.7%	$1.39M-11.6%	$1.44M-11.2%	$1.48M-27.5%	$1.53M-30.4%
Accrued Manufacturing Costs	$5.68M+42.9%	$12.43M+23.6%	$8M+29.3%	$5.64M+32.8%	$3.97M+35.9%
Other Commercial Liabilities	$8.56M+16.4%	$7.92M+9.6%	$6.48M+5.7%	$5.94M+15.4%	$7.35M+23.2%
Accrued Liabilities, Current	$8.56M+16.4%	$7.92M+9.6%	$6.48M+5.7%	$5.94M+15.4%	$7.35M+23.2%
Compensation and benefits	$5.68M+42.9%	$12.43M+23.6%	$8M+29.3%	$5.64M+32.8%	$3.97M+35.9%
Total debt	$3.79M-16.8%	$3.99M-15.8%	$4.18M-5.8%	$4.37M-12.3%	$4.56M-13.2%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$10K+11.1%	$10K+11.1%	$10K+11.1%	$10K+11.1%	$9K0.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Edgewise Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 22.61 — current assets exceed current liabilities.
Where does Edgewise Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.